Orfoxen 5.5 Mg (Orforglipron)

Description

Orfoxen 5.5 Mg is the supplied product name for a medicine containing orforglipron. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It belongs to a class of medicines studied and used for weight management and blood sugar control.

Before using any product labelled Orfoxen 5.5 Mg, its manufacturer, registration, active ingredient, and official prescribing information must be confirmed. A product name alone does not establish that the medicine is approved or suitable for a particular person.

The FDA approved orforglipron under the brand name Foundayo in April 2026 for adults with obesity or overweight with at least one weight-related medical condition. It is used alongside a reduced-calorie diet and increased physical activity.

The information below explains the verified medicine and identifies details that need confirmation for the Orfoxen brand.

The FDA-approved Foundayo label lists orforglipron tablets in strengths from 0.8 mg to 17.2 mg, including 5.5 mg.

Important: The verified Foundayo information does not prove that Orfoxen 5.5 Mg is manufactured by the same company or has the same formulation. Confirm the packaging and official registration before relying on the brand name.

What Is Orforglipron?

Orforglipron is an oral, non-peptide GLP-1 receptor agonist. It activates the human GLP-1 receptor, which is involved in appetite regulation, glucose control, and other body functions.

The medicine has been developed for weight management and type 2 diabetes. Its approved uses depend on the country, product, and official prescribing information.

Key Benefits

The verified FDA-approved use of orforglipron is to help adults with obesity, or adults with overweight and at least one weight-related medical condition, reduce excess body weight and maintain weight reduction long term. It is used with diet and increased physical activity.

Orforglipron has also received UK authorisation for weight management and improving blood sugar control in adults with type 2 diabetes.

These approved uses do not mean that every person will experience the same results. A prescriber must decide whether treatment is appropriate.

Active Ingredient

The active ingredient is orforglipron.

The official Foundayo label identifies the active ingredient as orforglipron calcium, with orforglipron as the active moiety. The 5.5 mg tablet contains 5.5 mg of orforglipron.

For Orfoxen 5.5 Mg, the exact inactive ingredients and formulation should be confirmed from the manufacturer’s official label.

How It Works

Orforglipron activates the GLP-1 receptor. This receptor is involved in regulating blood glucose and appetite.

GLP-1 receptor activation can:

Increase glucose-dependent insulin secretion.
Reduce glucagon secretion when blood glucose is elevated.
Slow stomach emptying.
Affect appetite and food intake.

The FDA describes orforglipron as a GLP-1 receptor agonist that activates the human GLP-1 receptor.

The medicine does not replace balanced nutrition, physical activity, or medical follow-up.

Indications and Uses

The approved uses of orforglipron depend on the country and product label.

Weight management

In the United States, Foundayo is approved for adults with obesity or overweight with at least one weight-related comorbid condition. It is used with a reduced-calorie diet and increased physical activity.

The UK authorised orforglipron for improving glycaemic control in adults with insufficiently controlled type 2 diabetes.

Do not assume that Orfoxen 5.5 Mg has the same approved indications. Check the medicine’s local registration and prescribing information.

Dosage and Administration

Do not use the information in this section as a personal dosing schedule.

The FDA-approved Foundayo label includes a specific dose-escalation plan and maximum daily dose. The correct dose depends on the official product label, treatment indication, and the patient’s medical circumstances.

A prescriber may need to consider:

The condition being treated.
Previous GLP-1 receptor agonist use.
Other medicines.
Side effects.
Kidney function.
The patient’s overall medical history.

Never change the strength, frequency, or duration of prescription medicine without professional guidance.

Available Strengths

The FDA label lists these Foundayo strengths:

The 5.5 mg strength is confirmed for Foundayo. Orfoxen’s exact product strengths and packaging remain unverified.

Available Pack Sizes

The official Foundayo label lists the 5.5 mg product in a bottle containing 30 tablets.

This does not establish the pack size of Orfoxen 5.5 Mg. Confirm the actual pack from the manufacturer or official product documentation.

How to Take

Orforglipron is an oral tablet. The official label provides instructions on how to take the approved product.

Patients should follow the instructions supplied with their prescribed medicine.

Do not:

Take more than the prescribed dose.
Change the dose without medical advice.
Use another person’s prescription.
Combine weight-management medicines without a prescriber’s guidance.
Use a product with an uncertain identity.

Who Can Use This Medicine?

The approved uses of orforglipron are for adults meeting the relevant medical criteria in the official label.

A qualified prescriber must assess whether the medicine is suitable. Age, medical history, other medicines, and the treatment indication all matter.

Who Should Not Use It?

The FDA-approved Foundayo label lists the following contraindications:

Personal or family history of medullary thyroid carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Known serious hypersensitivity to orforglipron or its ingredients.

This is not a complete safety assessment. The full prescribing information must be reviewed before treatment.

Warnings and Precautions

Orforglipron carries important warnings and precautions. The FDA label includes:

Thyroid C-cell tumors: The label includes a boxed warning regarding thyroid C-cell tumors. It states that the relevance of rodent findings to humans has not been determined.

Pancreatitis: Acute pancreatitis has been observed with GLP-1 receptor agonists. The label instructs that treatment should be discontinued if pancreatitis is suspected.

Severe gastrointestinal reactions: Severe gastrointestinal adverse reactions can occur. The label does not recommend Foundayo for patients with severe gastroparesis.

Kidney injury: Acute kidney injury may occur due to volume depletion. Renal function monitoring may be needed in patients experiencing reactions that could lead to dehydration.

Hypoglycemia: Using orforglipron with insulin or an insulin secretagogue may increase the risk of low blood sugar, including severe hypoglycemia. These warnings require professional medical assessment.

Possible Side Effects

The FDA-approved product information includes gastrointestinal adverse reactions among the important safety concerns.

Possible adverse effects and risks should be discussed with a prescriber. The exact frequency and severity depend on the official label.

Seek prompt medical attention for serious or concerning symptoms. Do not attempt to manage severe reactions by changing the medicine yourself.

Drug Interactions

The official label warns that concomitant use with insulin or insulin secretagogues may increase hypoglycemia risk.

Patients should provide their prescriber with a complete list of:

Prescription medicines.
Over-the-counter medicines.
Supplements.
Other GLP-1 receptor agonists.
Diabetes medicines.

A qualified professional should review the full interaction information before treatment.

Storage Instructions

Storage instructions should come from the official product label.

The FDA-approved Foundayo product is supplied in bottles with a desiccant and child-resistant closure.

For Orfoxen 5.5 Mg, the correct storage temperature, packaging, and handling instructions must be confirmed from the manufacturer’s documentation.

Keep prescription medicines out of the reach of children.

Manufacturer Information

The verified manufacturer of Foundayo is Eli Lilly and Company.

The manufacturer of Orfoxen 5.5 Mg has not been provided or verified. Do not publish a manufacturer name, factory address, or certification until it has been confirmed.

Prescription Requirements

Orforglipron is a prescription medicine. The FDA classifies Foundayo as a human prescription drug.

Patients should use prescription medicines only under the guidance of a qualified prescriber.

Conclusion

Orfoxen 5.5 Mg (Orforglipron) requires verified product information before publication as a medicine page. Orforglipron is an oral GLP-1 receptor agonist with approved uses that vary by country and product.

The FDA-approved product Foundayo includes a 5.5 mg tablet strength. However, this does not verify the Orfoxen brand.

Reliable medicine information should explain the active ingredient, approved uses, warnings, side effects, and prescription requirements. A qualified prescriber should assess whether treatment is appropriate.

Reviews

There are no reviews yet.

Be the first to review “Orfoxen 5.5 Mg (Orforglipron)”

We are here ready to support Health Medicine with free home delivery.

Email Address

Phone Number

Our Location